| CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 464 | 2021 |
| Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission A Rashidi, M Hamadani, MJ Zhang, HL Wang, H Abdel-Azim, M Aljurf, ... Blood advances 3 (12), 1826-1836, 2019 | 130 | 2019 |
| Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi … MJ Frank, NM Hossain, A Bukhari, E Dean, JY Spiegel, GK Claire, I Kirsch, ... Journal of Clinical Oncology 39 (27), 3034-3043, 2021 | 126 | 2021 |
| Diffuse large B‐cell lymphoma with primary treatment failure: ultra‐high risk features and benchmarking for experimental therapies LJ Costa, K Maddocks, N Epperla, NM Reddy, R Karmali, E Umyarova, ... American journal of hematology 92 (2), 161-170, 2017 | 89 | 2017 |
| Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies N Hossain, B Sahaf, M Abramian, JY Spiegel, K Kong, S Kim, ... Blood 132, 490, 2018 | 74 | 2018 |
| A meta-analysis of male breast cancer in Africa P Ndom, G Um, EMD Bell, A Eloundou, NM Hossain, D Huo The Breast 21 (3), 237-241, 2012 | 69 | 2012 |
| Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant … S Ahmed, JA Kanakry, KW Ahn, C Litovich, H Abdel-Azim, M Aljurf, ... Biology of blood and marrow transplantation 25 (9), 1859-1868, 2019 | 63 | 2019 |
| Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs … GSG Murthy, S Kim, ZH Hu, N Estrada-Merly, MB Abid, M Aljurf, U Bacher, ... JAMA oncology 8 (3), 404-411, 2022 | 59 | 2022 |
| Phase I trial using CD19/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL) LM Schultz, LS Muffly, JY Spiegel, S Ramakrishna, N Hossain, C Baggott, ... Blood 134, 744, 2019 | 56 | 2019 |
| Reduced intensity conditioned allograft yields favorable survival for older adults with B‐cell acute lymphoblastic leukemia AE Rosko, HL Wang, M de Lima, B Sandmaier, HJ Khoury, A Artz, ... American journal of hematology 92 (1), 42-49, 2017 | 56 | 2017 |
| Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph … MJ Wieduwilt, W Stock, A Advani, S Luger, RA Larson, M Tallman, ... Leukemia 35 (7), 2076-2085, 2021 | 46 | 2021 |
| Insights into the role of yeast eIF2A in IRES-mediated translation LC Reineke, Y Cao, D Baus, NM Hossain, WC Merrick PloS one 6 (9), e24492, 2011 | 40 | 2011 |
| Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy NM Hossain, S Dahiya, R Le, AM Abramian, KA Kong, LS Muffly, ... Leukemia & lymphoma 60 (2), 503-506, 2019 | 39 | 2019 |
| Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a center for international blood and … Z DeFilipp, R Ancheta, Y Liu, ZH Hu, RP Gale, D Snyder, HC Schouten, ... Biology of blood and marrow transplantation 26 (3), 472-479, 2020 | 34 | 2020 |
| Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis NN Shah, KW Ahn, C Litovich, TS Fenske, S Ahmed, M Battiwalla, ... Blood advances 2 (8), 933-940, 2018 | 34 | 2018 |
| Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by … A Lazaryan, M Dolan, MJ Zhang, HL Wang, MA Kharfan-Dabaja, DI Marks, ... haematologica 105 (5), 1329, 2019 | 30 | 2019 |
| Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma RF Cornell, A D'Souza, AA Kassim, LJ Costa, RD Innis-Shelton, MJ Zhang, ... Biology of Blood and Marrow Transplantation 23 (2), 269-277, 2017 | 28 | 2017 |
| C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy N Epperla, KJ Maddocks, M Salhab, JC Chavez, N Reddy, R Karmali, ... Cancer 123 (22), 4411-4418, 2017 | 27 | 2017 |
| Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation D Jagadeesh, NS Majhail, Y He, KW Ahn, C Litovich, S Ahmed, M Aljurf, ... Cancer 126 (10), 2279-2287, 2020 | 25 | 2020 |
| Myeloablative conditioning for allogeneic transplantation results in superior disease-free survival for acute myelogenous leukemia and myelodysplastic syndromes with low … N Bejanyan, M Zhang, K Bo-Subait, C Brunstein, H Wang, ED Warlick, ... Transplantation and cellular therapy 27 (1), 68. e1-68. e9, 2021 | 24 | 2021 |
